Ariana Pelosci

Patients with advanced gastric cancers tended to have better survival outcomes when given Opdivo plus chemotherapy, compared to those who were given chemotherapy alone.

Updated safety and subgroup analyses appear consistent with previously reported results from the phase 2 ZUMA-12 study of Yescarta for patients with high-risk large B-cell lymphoma.

The use of artificial intelligence to detect sentinel lymph nodes in patients with breast cancer may be able to save time and reduce costs as compared with immunohistochemistry.

The phase 3 FLAMES trial showed a benefit of progression-free survival with senaparib compared to placebo in patients with newly diagnosed, advanced ovarian cancer.

Patients with ER-positive, triple-negative metastatic breast cancer treated with a HER3-direct antibody drug conjugate obtained clinical responses with a positive safety profile.

Patients with HER2-low gastric cancer tended to have distinct characteristics compared to those with HER2-negative or -positive disease, warranting more research into this group, research found.

Adding Rivoceranib to pegylated liposomal doxorubicin — a type of chemotherapy — improved survival outcomes for patients with platinum-resistant ovarian cancer, according to recent study results.

Long-term follow-up shows that the CAR-T cell therapy Tecartus continues to elicit durable responses in patients with relapsed/refractory mantle cell lymphoma.

Patients with biliary tract cancer achieved a better survival outcome after receiving treatment with an oral antimetabolite following surgical resection than patients who only were treated with surgery.

The use of a ctDNA assay could help determine which patients with colorectal cancer may benefit most from chemotherapy after surgery.

Researchers hypothesized that metformin — a medication that helps lower insulin levels in patients with diabetes and is associated with inducing weight loss — might improve breast cancer outcomes.